OBJECTIVE: This study evaluated the immunogenicity, safety, and tolerability of a MF59-adjuvanted H5N1 vaccine in a population 6 months through 17 years of age. METHODS: Healthy subjects 6 to_36 months, 3 to_9 months, and 9 to_18 years of age were assigned randomly to receive 2 doses of either a MF59-adjuvanted H5N1 vaccine (7.5 _g/dose) or a MF59-adjuvanted trivalent seasonal influenza control vaccine (15 _g/dose for each antigen). Immunogenicity against the A/Vietnam/1194/2004-like vaccine strain was measured before and 3 weeks after the 2-dose primary series, through hemagglutination inhibition (HI), single radial hemolysis (SRH), and microneutralization. Local and systemic reactions were recorded. RESULTS: A total of 335 subjects received the H5N1 vaccine, and 137 subjects received the seasonal vaccine. Rates of seroprotection (HI titer of_40) against the H5N1 vaccine antigen were 97% for children 6 to 36 months and 3 to 9 years of age and 89% for older children. All subjects seroconverted in the SRH assay. Microneutralization titers of _40 were achieved by 99% of subjects, and _98% of subjects, respectively. Local reactions, particularly injection site pain in older children, were common, generally mild to moderate in nature, and transient and resolved spontaneously. Up to 5% of participants. There were no vaccine-related serious adverse events in either group. CONCLUSIONS: In this pediatric population, MF59-adjuvanted H5N1vaccine was highly immunogenic, had a good safety profile, reactogenicity comparable with that of an adjuvanted seasonal influenza control vaccine. Pediatrics 2010;126:e762–e770

Vesikari, T., Karvonen, A., Tilman, S., Borkowski, A., Montomoli, E., Banzhoff, A., et al. (2010). Immunogenicity and safety of MF59-adjuvanted H5N1 influenza vaccine from infancy to adolescence. PEDIATRICS, 126(4), 762-770 [10.1542/peds.2009-2628].

Immunogenicity and safety of MF59-adjuvanted H5N1 influenza vaccine from infancy to adolescence

MONTOMOLI, E.;
2010

Abstract

OBJECTIVE: This study evaluated the immunogenicity, safety, and tolerability of a MF59-adjuvanted H5N1 vaccine in a population 6 months through 17 years of age. METHODS: Healthy subjects 6 to_36 months, 3 to_9 months, and 9 to_18 years of age were assigned randomly to receive 2 doses of either a MF59-adjuvanted H5N1 vaccine (7.5 _g/dose) or a MF59-adjuvanted trivalent seasonal influenza control vaccine (15 _g/dose for each antigen). Immunogenicity against the A/Vietnam/1194/2004-like vaccine strain was measured before and 3 weeks after the 2-dose primary series, through hemagglutination inhibition (HI), single radial hemolysis (SRH), and microneutralization. Local and systemic reactions were recorded. RESULTS: A total of 335 subjects received the H5N1 vaccine, and 137 subjects received the seasonal vaccine. Rates of seroprotection (HI titer of_40) against the H5N1 vaccine antigen were 97% for children 6 to 36 months and 3 to 9 years of age and 89% for older children. All subjects seroconverted in the SRH assay. Microneutralization titers of _40 were achieved by 99% of subjects, and _98% of subjects, respectively. Local reactions, particularly injection site pain in older children, were common, generally mild to moderate in nature, and transient and resolved spontaneously. Up to 5% of participants. There were no vaccine-related serious adverse events in either group. CONCLUSIONS: In this pediatric population, MF59-adjuvanted H5N1vaccine was highly immunogenic, had a good safety profile, reactogenicity comparable with that of an adjuvanted seasonal influenza control vaccine. Pediatrics 2010;126:e762–e770
Vesikari, T., Karvonen, A., Tilman, S., Borkowski, A., Montomoli, E., Banzhoff, A., et al. (2010). Immunogenicity and safety of MF59-adjuvanted H5N1 influenza vaccine from infancy to adolescence. PEDIATRICS, 126(4), 762-770 [10.1542/peds.2009-2628].
File in questo prodotto:
File Dimensione Formato  
026-2010_PED-Vesikari.pdf

non disponibili

Tipologia: Post-print
Licenza: NON PUBBLICO - Accesso privato/ristretto
Dimensione 329.18 kB
Formato Adobe PDF
329.18 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11365/40085
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo